Cargando…

Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia

Detalles Bibliográficos
Autores principales:	Paneesha, S., Pratt, G., Parry, H., Moss, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192083/ https://www.ncbi.nlm.nih.gov/pubmed/32388230 http://dx.doi.org/10.1016/j.leukres.2020.106366

Ejemplares similares

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia
por: Parry, H., et al.
Publicado: (2021)

Long-Term Ibrutinib Therapy Reverses CD8(+) T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia
por: Parry, Helen M., et al.
Publicado: (2019)

COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia
por: Parry, Helen, et al.
Publicado: (2022)

NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma
por: Parry, Helen M., et al.
Publicado: (2016)

Hepatitis B Virus Reactivation in a Chronic Lymphocytic Leukemia Patient Treated with Ibrutinib
por: Choi, Jung Hye, et al.
Publicado: (2023)

Fatal Powassan virus encephalitis in patients with chronic lymphocytic leukemia
por: Johnson, Isla M., et al.
Publicado: (2022)

Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia
por: Tadmor, Tamar, et al.
Publicado: (2021)

Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia
por: Bennett, Rory, et al.
Publicado: (2023)

The clinical utility of polygenic risk scores for chronic lymphocytic leukemia
por: Sud, Amit, et al.
Publicado: (2021)

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
por: Muhowski, Elizabeth M., et al.
Publicado: (2022)

Unusual involvement of cervix and vulva in a case of chronic lymphocytic leukemia
por: Udupa, Karthik, et al.
Publicado: (2012)

Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia
por: Mozas, Pablo, et al.
Publicado: (2018)

Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia
por: Parry, Helen Marie, et al.
Publicado: (2016)

Antiretroviral therapy-naïve people living with HIV tend to have more severe symptoms of COVID-19
por: Sun, Jinfeng, et al.
Publicado: (2023)

Disseminated cryptococcal infection in a patient with treatment-naïve chronic lymphocytic leukemia (CLL)
por: Suleman, Adam, et al.
Publicado: (2019)

Identification of new putative driver mutations and predictors of disease evolution in chronic lymphocytic leukemia
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2019)

Types of second primary cancers influence survival in chronic lymphocytic and hairy cell leukemia patients
por: Zheng, Guoqiao, et al.
Publicado: (2019)

Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index
por: Wang, Yucai, et al.
Publicado: (2021)

Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia
por: Cerquozzi, Sonia, et al.
Publicado: (2015)

Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study
por: García-Martín, Paloma, et al.
Publicado: (2022)

MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene
por: Qin, Shu-Chao, et al.
Publicado: (2017)

ATM germline variants in a young adult with chronic lymphocytic leukemia: 8 years of genomic evolution
por: Royo, Romina, et al.
Publicado: (2022)

Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy
por: Popovic, Relja, et al.
Publicado: (2021)

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
por: Miao, Yi, et al.
Publicado: (2023)

Subclonal heterogeneity sheds light on the transformation trajectory in IGLV3-21(R110) chronic lymphocytic leukemia
por: Paschold, Lisa, et al.
Publicado: (2022)

A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
por: Pooler, Darcy B., et al.
Publicado: (2022)

Clinical and Cytogenetic Characterization, and Outcome of Chronic Lymphocytic Leukemia Patients in a Single Tertiary Center in Saudi Arabia
por: Al Mugairi, Areej, et al.
Publicado: (2023)

Progressive multifocal leukoencephalopathy developing in a fludarabine naïve patient with chronic lymphocytic leukemia
por: Ooi, Melissa G, et al.
Publicado: (2009)

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia
por: Hengeveld, P. J., et al.
Publicado: (2023)

Prognosis of IGLV3-21(R110) chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis
por: Hengeveld, Paul J., et al.
Publicado: (2023)

Upregulation of AXL and β-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance
por: Sinha, Sutapa, et al.
Publicado: (2021)

Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989–2018
por: van der Straten, Lina, et al.
Publicado: (2022)

Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection
por: Christopeit, Maximilian, et al.
Publicado: (2021)

DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease
por: Kost, Sara E. F., et al.
Publicado: (2023)

Comment on: “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”
por: Papamichos, Spyros I., et al.
Publicado: (2020)

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
por: Breccia, Massimo, et al.
Publicado: (2020)

Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia
por: Parry, Helen, et al.
Publicado: (2022)

Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion
por: Tam, Constantine S., et al.
Publicado: (2020)

High-Intensity Interval Training in Older Adults With Treatment Naive Chronic Lymphocytic Leukemia
por: Bartlett, David, et al.
Publicado: (2021)

Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study
por: Schetelig, Johannes, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cd47q3jokjjkaeasg7qfuuul8l